Abstract
At JADPRO Live 2025, Paula S. Kennedy-Newton, MSN, AGNP-C, discussed the underlying pathophysiology of neuroendocrine tumors (NETs), clinical presentation, diagnostic evaluation, the mechanisms of action and safety/efficacy data for NET therapies, and multidisciplinary care models to address the complex medical and psychosocial needs of patients living with NETs.
References
National Comprehensive Cancer Network. (2025). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors v3.2025. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
Singh, S., Halperin, D., Myrehaug, S., Herrmann, K., Pavel, M., Kunz, P. L., Chasen, B., Tafuto, S., Lastoria, S., Capdevila, J., García-Burillo, A., Oh, D. Y., Yoo, C., Halfdanarson, T. R., Falk, S., Folitar, I., Zhang, Y., Aimone, P., de Herder, W. W., Ferone, D.,…all the NETTER-2 Trial Investigators (2024). [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus highdose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study. Lancet (London, England), 403(10446), 2807–2817. https://doi.org/10.1016/S0140-6736(24)00701-3
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., Bushnell, D., O’Dorisio, T. M., Baum, R. P., Kulkarni, H. R., Caplin, M., Lebtahi, R., Hobday, T., Delpassand, E., Van Cutsem, E., Benson, A.,…NETTER-1 Trial Investigators (2017). Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. The New England Journal of Medicine, 376(2), 125–135. https://doi.org/10.1056/NEJMoa1607427
